推薦產品
產品名稱
Transglutaminase 2 Inhibitor, ZDON, A cell-permeable, peptide-based, irreversible inhibitor of transglutaminase 2 (TG2; IC₅₀ = 150 nM for recombinant TG2). Reacts with the active site cysteine of TG2.
品質等級
化驗
≥98% (HPLC)
形狀
powder
製造商／商標名
Calbiochem®
儲存條件
OK to freeze
顏色
off-white
溶解度
DMSO: 50 mg/mL
運輸包裝
ambient
儲存溫度
−20°C
一般說明
A cell-permeable, peptide-based (Z- QVPL) irreversible inhibitor of transglutaminase 2 (TG2) (IC50 = 150 nM for recombinant TG2) that acts by reacting with the active site cysteine of TG2. Exhibits far less potency against TG1 and TG3. Shown to significantly increase PGC-1a and cytochrome c mRNA levels in Q7 and Q111 cells (~50 mM). Also shown to enhance cytochrome c promoter activity by 250% in Q111 cells. Exhibits protective effect in cells exposed to 3-nitropropionic acid and NMDA, however, it does not directly affect mitochondrial bioenergetics.
警告
Toxicity: Standard Handling (A)
重構
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
其他說明
McConoughey, S. J., et al. 2010. EMBO Mol. Medicine.2, 349.
法律資訊
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 1
閃點（°F）
Not applicable
閃點（°C）
Not applicable
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。
Min-Su Han et al.
Scientific reports, 10(1), 13228-13228 (2020-08-09)
Transglutaminase 2 (TG2), also known as tissue transglutaminase, is a calcium-dependent enzyme that has a variety of intracellular and extracellular substrates. TG2 not only increases in osteoarthritis (OA) tissue but also affects the progression of OA. However, it is still
Manuel Lisetto et al.
International journal of molecular sciences, 24(15) (2023-08-12)
Transglutaminase 2 (TG2) is a multifunctional protein widely distributed in various tissues and involved in many physiological and pathological processes. However, its actual role in biological processes is often controversial as TG2 shows different effects in these processes depending on
Anurag Rathore et al.
Scientific reports, 10(1), 5350-5350 (2020-03-27)
The major barrier to a HIV-1 cure is the persistence of latent genomes despite treatment with antiretrovirals. To investigate host factors which promote HIV-1 latency, we conducted a genome-wide functional knockout screen using CRISPR-Cas9 in a HIV-1 latency cell line
Active Filters
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務
